Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Researchers are examining the effect of abelacimab compared to a placebo in patients with atrial fibrillation AF who are considered unsuitable for oral anticoagulation therapy. This Phase 3 study focuses on high-risk patients with AF to evaluate whether abelacimab can reduce the occurrence of ischemic stroke or systemic embolism. The study is led by Anthos Therapeutics, Inc. and aims to address treatment options in patients where traditional anticoagulation is deemed inappropriate. Participants are randomly assigned in equal numbers to receive either abelacimab 150 mg or a matching placebo by subcutaneous injection once a month. The study consists of three periods a screening period lasting up to 60 days, a double-blind treatment period that continues until at least 111 patients experience a primary endpoint event, and an end-of-treatment visit. Following this, participants may enter a 30-day follow-up or an optional open-label extension to receive abelacimab, depending on eligibility and regulatory approval. During the study, participants undergo assessments to monitor stroke, systemic embolism, and bleeding events, with the primary outcomes measured up to 30 months. Safety is tracked by recording bleeding events classified by the Bleeding Academic Research Consortium. Secondary outcomes include cardiovascular and all-cause mortality and other thrombotic events. The study also involves regular monitoring and follow-up visits to assess efficacy and safety throughout the treatment and observation periods.
Actively Recruiting
Researchers are studying the effects of PIPE-791 in adults aged 40 years and older with Idiopathic Pulmonary Fibrosis IPF, a lung disease characterized by progressive scarring. This Phase 2, randomized, double-blind, placebo-controlled global study aims to evaluate the efficacy, safety, tolerability, and how the body processes PIPE-791 in participants who may or may not be receiving other approved IPF treatments. The study is sponsored by Contineum Therapeutics and will enroll approximately 324 participants. Participants will be assigned to one of three groups two different daily oral doses of PIPE-791 or a placebo. The treatment period lasts 26 weeks. The full study duration extends up to 36 weeks, including screening before treatment and follow-up after treatment ends. Participants receive their assigned tablets daily during the treatment phase. Throughout the study, participants will undergo lung function tests such as forced vital capacity FVC, high-resolution CT scans to assess lung fibrosis, and safety monitoring for any side effects or adverse events. Researchers will track changes in lung function and overall health from the start of treatment to week 26, with additional safety follow-up until week 30. The study involves regular visits for assessments, and participant involvement may last up to 36 weeks in total.